FIRECREST Customer Support

As ADCs expand into new indications—including rare cancers and potential autoimmune applications—regulatory pathways continue to adapt. ICON’s regulatory expert, Eilidh Mayer, examines how accelerated approvals, orphan ...

With increasing approvals across Asia and beyond, ADCs remain one of the most dynamic areas in oncology innovation. ICON’s new publication highlights the critical elements of regulatory engagement, dose optimisation and ...

ICON and Advarra have entered a new partnership to introduce a ‘research-ready’, connected site network model that will transform how clinical trials are operationalised globally. The model will integrate ICON’s clinica...

Meet with ICON experts at the GLP-1-Based Therapeutics Summit to gain valuable insights on obesity clinical development and learn about our ready-to-deploy infrastructure designed to accelerate obesity and comorbidity pr...

How to navigate EU MAA Regulations and Registration For Chinese pharma and biotech companies looking to expand into the European Union’s market of over 450 million people, the first step is to understand the significant...

ICON is heading to #AMCP2026 from 13–16 April, and our team is looking forward to engaging with leaders across the managed care and market access community. Visit us at booth \#1412 to learn how ICON’s evidence generatio...

Earlier this month, our teams across ICON came together around the world to celebrate International Women’s Day. From team celebrations and office events to shared moments of reflection, this year’s theme, Give to Gain,...

Accellacare, ICON’s clinical research network, offers a wide range of stand-alone and integrated solutions to increase patient access to innovative treatments. Meet us at #WorldVaccineCongress, booth 222 to learn how o...

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth \#31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small mole...